The use of tumor necrosis factor a (TNFa) inhibitors such as infliximab, etanercept, and adalimumab for various autoimmune diseases, including Crohn's disease (CD) and ulcerative colitis (UC), has increased in the past few years. While associated with symptomatic relief in many patients, the use of
Acute hepatic cytolysis following H1N1 vaccination in a patient with Crohn's disease on infliximab
β Scribed by Claire Pillot; Jean-Baptiste Chevaux; Nadine Petitpain; Laurent Peyrin-Biroulet
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 40 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Immunosuppressive therapy with anti-tnf-alpha antibodies is effective in patients with inflammatory bowel disease (ibd). however, there is an increased risk for infections associated with this therapy. ## Methods: Here, we report the case of a 58-year-old patient with crohn's disea
FIGURE 1. MRI of the spleen. a: T1-weighted image on dynamic contrast-enhancement (axial). b: T1-weighted image on dynamic contrast-enhancement (coronal).
To the Editor: Immunomodulatory therapies such as 6-mercaptopurine (6-MP) and azathioprine provide high remission rates and success in avoiding steroid dependence in patients with inflammatory bowel disease (IBD). However, these treatments are not without adverse effects including leukopenia, liver